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Many organ systems exhibit signiﬁcant age-related deﬁcits, but, based on studies in old rodents and elderly humans, the liver
appearstoberelativelyprotectedfromsuchchanges.Aremarkablefeatureoftheliverisitscapacitytoregenerateitsmassfollowing
partialhepatectomy.Reportssuggeststhatagingcompromisestheliver’sregenerativecapacity,bothintherateandtotheextentthe
organ’s original volume is restored. There has been modest deﬁnitive information as to which cellular and molecular mechanisms
regulating hepatic regeneration are aﬀected by aging. Changes in hepatic sensitivity to growth factors, for example, epidermal
growthfactor(EGF),appeartoinﬂuenceregenerationinoldanimals.Studieshavedemonstrated(a)a60%declineinEGFbinding
to hepatocyte plasma membranes, (b) reduced expression of the hepatic high aﬃnity EGF receptor and (c) a block between
G1 and S-phases of the cell cycle in old rats following EGF stimulation. Recent studies suggest that reduced phosphorylation
and dimerization of the EGF receptor, critical steps in the activation of the extracellular signal-regulated kinase pathway and
subsequent cell proliferation are responsible. Other studies have demonstrated that aging aﬀects the upregulation of a Forkhead
Box transcription factor, FoxM1B, which is essential for growth hormone-stimulated liver regeneration in hepatectomized mice.
Aging appears to compromise liver regeneration by inﬂuencing several pathways, the result of which is a reduction in the rate of
regeneration, but not in the capacity to restore the organ to its original volume.
1.Introduction
On the one hand, the liver, unlike most other organs,
does not exhibit well-documented or marked changes in
either structure or function during the aging process (see
[1–4] for reviews). There have been few comprehensive
studies on liver morphology during aging; most have been
performed using rodent models and have been qualitative in
nature. Studies using human liver tissue have suﬀered from
dependence on postmortem samples or on samples from
subjects diagnosed with liver disease. There is quantitative
evidence that hepatocytes in males of one inbred rat strain
(Fischer 344) increase in volume through maturity and,
subsequently, become smaller such that the size of cells in
immature and senescent animals is equivalent [5]. Other
changes in hepatocellular structure include (a) a loss of
smooth surfaced endoplasmic reticulum, (b) an increase in
the volume of the dense body compartment, for example,
secondary lysosomes, residual bodies, or lipofuscin, and
(c) an increase in hepatocyte polyploidy (see [6]f o ra
review). None of these age-related changes is manifested in
signiﬁcant declines in hepatic function(s).
On the other hand, there are data that demonstrate spe-
ciﬁc age-related changes, including a loss of hepatic volume
and a decline in hepatic perfusion; both of which may aﬀect
certainliverfunctions,suchasﬁrstpasspharmacokinetics[7,
8]. However, data from clinical liver function tests are incon-
clusive and fail to identify signiﬁcant age-associated deﬁcits
in hepatic functions ([9, 10], see [2] for a review). Several
studies, including our own, have demonstrated moderate
age-related changes in biliary function, including decreased
bile ﬂow and bile acid secretion ([11], see [3] for a review).
The clearance of drugs that undergo mandatory Phase I
hepatic metabolism may be compromised in the elderly (see
[12]forareview).However,thereislittleevidencetosupport
the hypothesis that reduced hepatic drug clearance reﬂects
concomitant declines in the amounts or eﬃcacies of human
livercytochromeP-450 isoforms[13].Arecentreviewargues2 Current Gerontology and Geriatrics Research
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Figure 1: Eﬀect of animal age on liver volume at two intervals
following partial hepatectomy in young and old rats. Data derived
from [15].
that substantial age-related declines occur in hepatic Phase
I drug metabolism as evidenced by reduced clearance of
high-clearance drugs and that other data are misleading
since most studies have assessed protein-bound plus free-
drug concentrations (total clearance) rather than separating
these two components [14]. It should be noted that drug
clearance reﬂects several variables, including volume of
distribution, protein binding, intrinsic hepatic metabolism,
and renal clearance. While there are data suggesting that
certain low-protein binding drugs exhibit reduced clearance
in the elderly; the evidence for a similar decline in free-
drug clearance is less viable. Studies by us and by others
assessing the eﬃcacy of speciﬁc P-450 isoforms across
a broad age spectrum in humans suggest that intrinsic
cytochrome P450-mediated hepatic drug metabolism, not
total drug clearance, remains unchanged in humans as a
function of age [12, 13]. The question of whether or not
liver functions are compromised in senescent animals or
elderly humans remains unclear. The late hepatologist, Hans
Popper, stated that “aging exerts a limited eﬀect on the
constitutive functions of the liver and more on its response
to extrahepatic factors...”[ 14].
Perhapsamoreclinicallysigniﬁcantage-relatedchangeis
a marked decline in the rate of hepatic regeneration follow-
ing partial resection (hepatectomy) or chemically induced
injury. This is manifested as a delay in hepatocyte prolifera-
tion following hepatectomy and is documented by a number
of studies, including that of Popper [16]( Figure 1). The pur-
pose of this brief review is to present a perspective of the cur-
rent understanding of the cellular and molecular factors and
mechanismsthatcontributetothediminishedhepaticregen-
eration rate in old-animal models and in elderly humans.
2. Basics of LiverRegeneration
First, hepatocytes constitute a population of highly diﬀeren-
tiated, quiescent, yet intermitotic cells with few cells under-
going division at any one time, for example, approximately
Partial hepatectomy
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Regenerated liver
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Time after hepatectomy
S-phase S-phase
Figure 2: Eﬀect of age on the number of hepatocytes entering
S-phase and the rate of liver regeneration following partial hepa-
tectomy.
1 mitotic ﬁgure per 20,000 cells in the resting liver. Second,
the normal regenerative process reﬂects a global hyperplasia,
that is, compensatory growth and division of existing hepa-
tocytes, rather than a cellular hypertrophy or a primary
stem cell response. Third, the regenerative process is highly
regulated by signal transduction pathways (see [17]f o ra
review). Fourth, the initiation of hepatocyte proliferation
or liver regeneration requires the activation of speciﬁc cell
cycle and mitogenic genes, as well as the repression of those
genes responsible for inhibiting hepatocyte proliferation in
the resting organ. The consensus is that fewer hepatocytes
in senescent animals and elderly humans enter S-phase after
partial hepatectomy in comparison to younger subjects, and
those that do so less rapidly and that this age-related delay
compromises the rate of liver regeneration (Figure 2).
3. Why the Concern about Compromised Liver
Regeneration in the Elderly?
One reason is the marked increase in mortality due to
liver disease in elderly subjects in comparison to younger
populations. Regev and Schiﬀ reported 3–5-fold increases
in deaths due to liver diseases in the over 65 population
versus those under 45 years of age [18]. Another basis
for concern is the increased demand for donor livers for
transplantation. This issue is complex since there is an eﬀort
to increase the age limits for liver donors and, to some
extent, of liver recipients. On the one hand, there is evidence
that livers from older donors may be less viable than those
from young donors [19, 20]. Recipient age should also be a
consideration since Fortner and Lincer reported that post-
transplant mortality increases by 15% between 55 and 75
years of age [21]. On the other hand, there are data that
suggest that the impact of age is modest with respect to
recipient and graft survival, at least during the ﬁrst few
post-transplantation years. For example, both recipient and
graft survival rates decline in elderly patients receiving livers
from old donors by only 10–15% over the ﬁrst three post-
transplant years [22–24].
In summary, aging does impair liver regeneration with
respect to the rate of hepatocyte proliferation followingCurrent Gerontology and Geriatrics Research 3
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Figure 3: Eﬀect of aging on telomere length in human hepatocytes.
Both Takubo et al. and Aikata et al. (not shown) determined
hepatocyte telomere length to be between 5–10kbp in humans 80
years of age. Data derived from [26, 27].
resection. The magnitude of this impairment does not seem
to be excessive and, furthermore, may not be an impediment
to the use of livers from elderly donors. However, before
we can assess this option deﬁnitively, we need to clearly
understand the cellular and molecular mechanisms that
compromise liver regeneration in the elderly. There have
been a number of hypotheses, some of which are discussed
below. Perhaps the most comprehensive studies on this
subjecthavebeenperformedby Timchenko’s group(see [17]
for a review).
4. Age-Related Increasesin Reactive Oxygen
Species,HepatocellularResidualBodies,
andLipofuscin
One suggestion is that the documented age-related increase
in residual bodies or lipofuscin in hepatocytes reﬂects
an inability to eliminate cellular waste products and that
this accumulation compromises normal cell activities (see
[25] for a review). Our quantitative electron microscopic
analysis demonstrated a 3-4-fold increase in the volume
of this intracellular compartment during aging in rats [5].
However, since this compartment accounts for only about
1% of the total intracellular volume of hepatocytes, it seems
inappropriate to assign this particular age-related shift a
signiﬁcant role in impeding hepatocyte proliferation and
liver regeneration.
Reactive oxygen species (ROS) have been considered a
causative factor responsible for a number of pathophys-
iological changes during aging. A recent study by Haga
et al. implicates increased expression/phosphorylation of
the adapter protein p66Shc in the enhanced generation of
ROS and in initiating apoptosis in hepatocytes after partial
hepatectomy in aged mice, but not in the livers of young
animals [29]. In this study, hepatocyte proliferation in
both young and old cohorts was similar, but cell growth
was impaired only in the old mice. Furthermore, ablation
of p66Shc diminished posthepatectomy oxidative stress and
apoptosis in aged mice, suggesting that this age-associated
protein may play a critical role in inhibiting the hepatic
regenerative capacity in old animals.
Gielchinsky et al. recently reported an interesting obser-
vation that may have clinical ramiﬁcations for enhancing
hepatic regeneration in the elderly, at least in elderly
women [32]. These investigators reported that (a) the post-
hepatectomy regenerative rate was restored in aged pregnant
mice in comparison to their age-matched, nonpregnant
cohorts and (b) this regeneration was achieved primarily
by hepatocyte hypertrophy rather than by cell proliferation,
the process responsible for normal liver regeneration. The
clinical potential resides in the possible pharmacological
activation of an important mediator of hepatocyte growth,
the Akt/mTPRC1 pathway, and the subsequent switch from
ac e l lp r o l i f e r a t i v et oac e l lg r o w t hr e s p o n s e .
5. Age-Related Loss of Telomere Length
Another hypothesis suggests that an age-related reduction in
hepatocyte telomere length results in diminished cell mitosis
and apoptosis and, thus, a decline in cell proliferation.
For example, Takubo et al. demonstrated a marked age-
associated loss in hepatocyte telomere length in humans, and
these data were conﬁrmed independently by Aikata et al.
[26, 33]( Figure 3). Takubo et al. also reported that the rate
at which telomere shortening occurred was markedly higher
in hepatocytes in comparison to most other epithelial cell
types with high turnover rates, for example, enterocytes and
esophageal epithelium [26]. A recent review suggests that the
yearly reduction rate in human hepatocyte’s telomere length
ranges between 55 and 120 base pairs [27].
Obvious changes in cell structure are not always reﬂected
in concomitant functional alterations. Using a telomere
restriction fragment deﬁcient mouse model, Denchi et al.
demonstrated that the loss of telomere integrity did not
compromise liver regeneration following partial hepatec-
tomy [35]. Although the hepatocytes enter S-phase, subse-
quent mitosis, anaphase, and telophase did not occur. This
paper is of particular interest since it demonstrates that
mouse hepatocytes subjected to the deletion of a telom-
ere protection protein, TRF2, exhibit frequent telomere
fusions, but no evidence of apoptosis or loss of hepatic
function(s). Furthermore, post-hepatectomy regeneration
was not compromised, but was accomplished via increased
cell growth yielding polyploid cells, perhaps indicative of
a switch from a proliferative to a cell growth pathway
[32].
Interestingly, our stereological analyses showed that
mean hepatocyte volume in male F344 rats decreases
between 20 and 30 months of age such that cells in the livers
of the oldest animals were similar in volume to those in
very young animals [5]. Our data also demonstrated that
the relative number of binucleate hepatocytes, the nuclear
numerical density, and the nucleocytoplasmic volume ratio
were similar in the youngest and oldest rats. However, these
studies were performed on resting hepatocytes, and the data
do not preclude the possibility that small hepatocytes in4 Current Gerontology and Geriatrics Research
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Figure 4: Eﬀect of age on hepatocyte response to EGF and serum
growth factors in young and old resting and posthepatectomy
rats. Note that the posthepatectomy responses to both EGF (PHX)
and EGF/serum were signiﬁcantly greater in the young rats in
comparison to their older cohorts. Data derived from [28].
senescent rats lack the capacity to undergo hypertrophy in
response to mitogenic factors.
The recent observation that rejuvenating telomerase
activity in a telomerase-deﬁcient mouse model reversed
certain well-documented age-related deﬁcits may lend cre-
dence to further studies on liver regeneration in this model
[36]. The caveat, however, is that aging in this particular
telomerase-deﬁcient mouse model may not correctly reﬂect
normal human aging. A recent review by Hoare et al.
provides a comprehensive discussion of the relationships
between aging, hepatocyte telomere shortening, and hepatic
injury or disease [37].
6.Effect ofAging on the Hepatocellular
Response to GrowthFactors
Twenty years ago, Sawada demonstrated that the hepatocyte
proliferative response to EGF was markedly greater in young
rats in comparison to old animals and suggested that aging
impaired the responsiveness of the cells in old rats to growth
factors [28]( Figure 4). These studies provided impetus to
the controversy concerning the impact of aging on the
hepatocyteproliferativeresponsetogrowthfactors.Forsome
years, researchers have suspected that aging impairs speciﬁc
growth-regulating molecules and/or their receptors, which,
in turn, compromises the regenerative response. Despite
Sawada’sobservationthatoldhepatocytesdidnotrespondto
EGFstimulationaswellasdidlivercellsfromyounganimals,
they also reported that there were no age-related losses in
either the number of hepatocellular EGF receptors or in
their binding aﬃnity. However, Marti, in our laboratory,
demonstrated a 60% age-related decline in EGF binding to
hepatocyte plasma membranes in rats [38]. Interestingly,
Ishigami et al. almost simultaneously reported the absence of
any age-related change in hepatocyte EGF binding capacity,
but did report a marked decline in EGF-induced DNA
synthesis [39]. It should be noted that Ishigami et al. used
primary hepatocyte cultures, whereas Marti et al. used
hepatocyte plasma membranes isolated from intact livers.
The preparation of primary hepatocyte cultures involves
the use of collagenase and other enzymes that cleave hep-
atocyte surface proteins nonspeciﬁcally, for example, EGF
receptors, resulting in cells from both young and old donors
expressing equivalently diminished numbers of receptors.
The isolation of hepatocellular plasma membranes does not
employ enzymes, and the inherent number of receptors
and, assumedly, their aﬃnity for their ligand(s) remain
intact during this procedure. Interestingly, we observed an
80% age-related decline in the amount of radiolabeled EGF
associated with rat hepatocyte nuclei [40]. Furthermore,
Ohtake et al. reported age-related losses of the hepatocyte
high-aﬃnity EGF receptor as well as in the level of receptor
phosphorylation, a critical step in EGF activation [41].
Several studies have reported diminished activation of
a hepatocyte extracellular receptor kinase (ERK) in old
rodents in comparison to young animals following partial
hepatectomy [30, 31]. This decline leads to reduced EGF
receptor phosphorylation and, subsequently, to decreased
binding of the adapter protein, Shc, to the receptor, a
critical event in the EGF-induced hepatocyte proliferation
pathway (Figure 5). Subsequent studies by Kamat and others
focused on the molecular pathways that regulate hepatocyte
proliferation [34]. These investigators reported signiﬁcant
age-related declines in the expression of hepatocyte EGF
receptor mRNA and protein, as well as in EGF receptor
phosphorylation and the subsequent activation of ERK
(Figures 6 and 7).
Growth hormone (GH) is another mitogenic factor that
has been implicated in hepatic regeneration. Krupczak-
Hollis et al. reported that GH treatment of old, partially
hepatectomized rats enhances hepatocyte proliferation in
comparison to similarly aged, nontreated cohorts [42].
Furthermore, the endogenous hepatocellular levels of GH
and its receptor decline with age, whereas the level of cyclin
D3, which activates C/EBPα (CCAAT/enhancer-binding
proteins) phosphorylation, increases. This phosphorylation
enhances C/EBPα complexing with (a) a retinoblastoma
geneproduct,(b)achromosomalremodelingprotein(Brm),
and (c) a histone deacetylase to yield an inhibitor of a
transcription factor required for hepatocyte proliferation,
the Forkhead Box gene, FOXM1B.
The importance of transcription factors in the liver
regeneration process has been illustrated in a series of
studies by Wang and associates delineating the critical role
played by the FOXM1B gene in hepatocyte proliferation
[43, 44]. Using a mouse model deﬁcient in FOXM1B,
these investigators showed that adenovirus transfection with
FOXM1B restored the liver regenerative capacity in mature
animals to a level that exceeded that measured in young
adult mice. Nontransfected FOXM1B-deﬁcient mice did not
exhibit enhanced hepatocyte proliferation.Current Gerontology and Geriatrics Research 5
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Figure 5: Eﬀect of age on hepatic EGF receptor activation. Data derived from [30, 31].
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Figure 6: Eﬀect of age on liver EGF activation, phosphorylation, and subsequent activation of the extracellular receptor kinase (ERK). Data
derived from [34].
In the resting liver, the hepatocellular levels of cyclin D3
and C/EBPα are high, thus inhibiting hepatocyte prolifera-
tion. In senescent animals, the cyclin D3 level remains high,
activating the phosphorylation of C/EBPα and enhancing
the formation of the larger proliferation inhibitory complex.
However, following partial hepatectomy in young adult
animals, the cyclin D3 level drops, as does the level of
the inhibitor, C/EBPα, permitting the expression of essen-
tial transcription factors, for example, FOXM1B and cell
cycle genes, and, ultimately, rapid hepatocyte proliferation
(Figure 8).
Recently, Chen and colleagues identiﬁed a mechanism
that regulates FOXM1B transcriptional activation and the
liver regeneration process [45]. These researchers showed
that the farnesoid X receptor (FXR), a transcription factor
that regulates a variety of metabolic pathways, is critical
for liver regeneration since FXR-deﬁcient mice exhibit a
diminished regenerative capacity. In addition, FOXM1B was
identiﬁed as a direct FXR target gene, and diminished FXR
binding to FOXM1B may contribute to decreased hepatocyte
regeneration in the elderly.
7. Other Possible Causesof
DiminishedRegeneration
A series of studies by Le Couteur et al. reported marked
age-related changes in the structure of the hepatic sinusoidal
endothelium, including a loss of fenestrae and a thickening6 Current Gerontology and Geriatrics Research
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Figure 8: Proposed eﬀect of aging on the molecular factors that
regulates hepatocyte proliferation following partial hepatectomy.
of the endothelial cells, a process referred to as pseudo-
capillarization [46–48]. Interestingly, a very recent paper
by Furrer et al. has suggested that pseudocapillarization
contributes to the age-related decline in the regenerative
response in a posthepatectomized murine model [49]. These
investigators demonstrated enhanced liver regeneration in
old mice following treatment with a serotonin receptor
agonist, and this response correlated with an increase in the
number of endothelial cell fenestrae. Their data suggest that
the serotonin receptor agonist enhances systemic vascular
endothelial growth factor (VEGF) availability, which, in
turn, regulates endothelial cell fenestrae diameters, thus
improving hepatic perfusion and restoring the hepatic
regenerative capacity. However, evidence for or against age-
related declines in serotonin and/or VEGF receptors will
require deﬁnitive ligand-binding studies.
In summary, there are several conclusive statements and
a few evidence-based speculations concerning the eﬀect
of age on the process of liver regeneration that warrant
consideration, including the following.
(i) Liver regeneration is compromised in old animals
and in elderly humans.
(ii) The rate of liver regeneration, rather than the regen-
erative capacity, is diminished in the elderly.
(iii) Theinduction ofhepatocyte proliferationfactorsand
the expression of cell cycle genes is inhibited in the
elderly.
(iv) The repression of cell proliferation and cell cycle gene
inhibitors is compromised in the elderly
(v) The relative eﬃcacies of normal, cell-cycle-induced
hepatocyte proliferation versus an independent path-
way involving hepatocyte hypertrophy in maintain-
ing liver functions requires additional study.
(vi) The roles of VEGF, serotonin, and liver sinusoidal
pseudocapillarization require further investigation.
Most evidence supports the concept that the age of the
liver donor or recipient exerts only a modest impact on post-
transplantation patient’s survival. These studies suggest that
a pretransplantation regimen of growth factors in potential
elderly liver recipients merits further consideration.
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